Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF)'s (Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF)) CEO Danny Lee and CFO David Cocke present the details of their full year trading update to Proactive London.
Total revenue was £14.4m, representing a 13% increase on the prior year with their cash position of £5.7m at year end.
Danny says 2021 was another challenging year for healthcare due to the COVID variants but that the firm managed to tackle those obstacles, performing 'admirably as it manoeuvred around the
delay of elective surgeries, fluid healthcare guidance and directives, supply chain disruptions and personnel shortages'.